



Published in final edited form as:

Mol Psychiatry. 2022 January ; 27(1): 652–668. doi:10.1038/s41380-021-01080-7.

Astrocytes in Cocaine Addiction and Beyond

Junshi Wang^{1,2}, Leanne M. Holt², Hugh H. Huang³, Susan R. Sesack¹, Eric J. Nestler^{2,*}, Yan Dong^{1,*}

¹Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260

²Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029

³Coriell Institute for Medical Research, Camden, NJ 08103

Abstract

Drug addiction remains a key biomedical challenge facing current neuroscience research. In addition to neural mechanisms, the focus of the vast majority of studies to date, astrocytes have been increasingly recognized as an “accomplice.” According to the tripartite synapse model, astrocytes critically regulate nearby pre- and postsynaptic neuronal substrates to craft experience-dependent synaptic plasticity, including synapse formation and elimination. Astrocytes within brain regions that are implicated in drug addiction exhibit dynamic changes in activity upon exposure to cocaine and subsequently undergo adaptive changes themselves during chronic drug exposure. Recent results have identified several key astrocytic signaling pathways that are involved in cocaine-induced synaptic and circuit adaptations. In this review, we provide a brief overview of the role of astrocytes in regulating synaptic transmission and neuronal function, and discuss how cocaine influences these astrocyte-mediated mechanisms to induce persistent synaptic and circuit alterations that promote cocaine seeking and relapse. We also consider the therapeutic potential of targeting astrocytic substrates to ameliorate drug-induced neuroplasticity for behavioral benefits. While primarily focusing on cocaine-induced astrocytic responses, we also include brief discussion of other drugs of abuse where data are available.

Keywords

astrocytes; cocaine; addiction; nucleus accumbens; synaptic plasticity; synaptogenesis

Introduction

The term glia is derived from “glue” in Greek, but glia functions go far beyond simply providing structural and metabolic support to neurons. The abundance of glial cells progressively and substantially increases along both evolutionary phylogeny and brain

<p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms</p>

*Corresponding Authors: Dr. Yan Dong, Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, Phone: 412-624-3140, yandong@pitt.edu, Dr. Eric J. Nestler, Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1065, New York, NY 10029, eric.nestler@mssm.edu.

Declaration: The authors declare no financial interests.

complexity¹. For example, the astrocyte-to-neuron ratio in human brains (~1–1.4:1) is higher than that in rodents (~0.4:1) or *C. elegans* (~0.2:1)^{2–5}. While human brains have higher metabolic demands, such a high ratio would appear to be an excessive number of astrocytes for just structural and metabolic support. Indeed, astrocytes—the most prevalent type of glia—are substantially larger in human brains, with more sophisticated morphologies that contact more synapses than any other species^{6, 7}. Furthermore, the propagation speed of intracellular Ca²⁺ waves in human astrocytes is ~4-fold faster than in rodents⁶. Human-originated astrocytes maintain their enhanced cellular features when engrafted and induced in the mouse brain, resulting in enhanced experience-dependent synaptic plasticity and improved learning in these chimeric mice⁸. Such results suggest that astrocytes not only participate in brain metabolism and stability, but also are key substrates defining the brain's cognitive capacity^{9–13}.

Astrocytes are broadly known for their role in neurotransmitter and ionic homeostasis, synaptic and neuronal modulation, and blood-brain barrier maintenance. Astrocytes exhibit a complex morphology, with primary branches extending and elongating into delicate terminal leaflets, called peripheral astrocyte processes. Such perisynaptic processes enwrap the pre- and postsynaptic components of synapses, and these interactions occur at a distance as small as 10 nm, indeed closer than the width of some synaptic clefts^{14–16}. An array of neurotransmitter receptors and transporters are expressed in astrocytes, highlighting that astrocytes may respond directly to neuronal signals^{17–22}. Astrocytes can release substances into the extracellular space via anion channels, unpaired hemichannels of gap junctions, transporters or exchange antiporters, and other forms of non-vesicular release^{23–26}. On the other hand, components of the basic machineries that mediate Ca²⁺-dependent vesicular release by exocytosis have been detected in astrocytes, including vesicular glutamate transporters (VGLUT1/2) and the SNARE protein cellubrevin²⁷. While the exact mechanisms and physiological relevance remain under debate^{28, 29}, vesicular release of substances from astrocytes has been detected in many experimental conditions^{30–34}. Among astrocyte-secreted factors, some are classic neurotransmitters and neuromodulators, such as glutamate and adenosine triphosphate (ATP), while others are unique to astrocytes. With these mechanisms, astrocytes are thought to reciprocally communicate with neurons and regulate synaptic transmission³⁵ through a structural complex, termed the “tripartite synapse” (Figure 1), composed of a presynaptic nerve terminal and a postsynaptic dendritic spine enveloped by astrocyte processes, now viewed as the basic unit of synaptic transmission^{35, 36}. Increasing evidence suggests that astrocytes display significant regional heterogeneity and specificity in the brain³⁷, although much remains to be learned about the molecular and cellular basis, and functional consequences, of such regional differences.

Delineating the precise mechanistic underpinnings of drug addiction remains a key research goal for the neuroscience community. A defining feature of drug addiction in humans is the high rate of relapse even after prolonged drug abstinence, which is often triggered by re-exposure to environmental cues that were previously associated with drug experience. Rodent studies reveal that cue-induced cocaine seeking and relapse are mediated in part by altered glutamatergic synaptic transmission within the nucleus accumbens (NAc), a brain region that has been critically implicated in reward learning and motivated behaviors^{38–41}. The vast majority of studies of cocaine's action on the brain have concentrated on neurons.

However, increasing evidence suggests that astrocytes play a dynamic role in the formation and maintenance of maladaptive changes at glutamatergic synapses in the NAc and related limbic regions during cocaine experience, promoting cocaine seeking and relapse after drug withdrawal^{42–45}. Here, we discuss cellular features of astrocytes and their involvement in addiction-related neuronal changes at the synapse and circuit levels.

Basic features of astrocytes

Ca²⁺-mediated astrocyte activity

Astrocytes do not generate action potentials. Rather, information sensing and signaling output by astrocytes is thought to be mediated in part by intracellular Ca²⁺ transients^{46, 47}. These transients can be mediated through G protein-coupled receptors (GPCRs) and their activation of IP3-activated type 2 receptors (IP3R2) on the endoplasmic reticulum (ER) of astrocytes, resulting in ER release of Ca²⁺ and elevation of intracellular Ca²⁺ levels (Figure 1)^{48–52}. In addition, ionotropic receptors may mediate Ca²⁺ influx into astrocytes (Figure 1)^{53, 54}. Through these various types of mechanisms, astrocytes respond to neuron-derived signaling molecules and generate several patterns of intracellular Ca²⁺ waves in a finely graded and subcellularly heterogeneous manner. In contrast to neural networks that are composed of spatially separated neurons, astrocytes can directly couple with neighboring astrocytes via gap junctions^{55, 56}. In this manner, up to dozens of astrocytes are connected to form an electrically low-resistance reticular system called a syncytium. This network of coupled astrocytes is a key feature of astrocyte biology, which is found throughout the central nervous system and across many species^{56, 57}. Interestingly, not all neighboring astrocytes directly couple, for example, astrocyte networks within the somatosensory cortex largely follow a single barrel⁵⁶. Regardless, an astrocyte syncytium can cover the space of hundreds of microns in diameter with millions of synapses contained therein. Depending on the physiological condition, the Ca²⁺ waves can be restricted within one astrocyte or, alternatively, propagate to other astrocytes via the syncytium for synchronous network effects^{58, 59}.

Early studies focused on astrocytic Ca²⁺ activities within the cell soma, since ER storage was viewed as the predominant source of Ca²⁺ for the entire astrocyte^{28, 60}. Improvements in the spatiotemporal detection of Ca²⁺ now demonstrate active Ca²⁺ signals throughout an astrocyte—with subcellular localizations and microdomains that exhibit dynamic features of these Ca²⁺ transients^{29, 61, 62}. In fact, Ca²⁺ signals are detected in far distal astrocytic processes⁶², and can be independent of somatic Ca²⁺ sources^{61, 63}.

One potential consequence of these localized Ca²⁺ events is ‘gliotransmission’⁶¹. Ca²⁺ signaling in astrocytes is far from straightforward, however. While Ca²⁺-induced gliotransmission and resulting synaptic regulation have been observed frequently^{64–70}, it has also been shown that Ca²⁺ elevations in astrocytes are not always associated with the release of gliotransmitters⁷¹, suggesting a subtle and complex relationship between astrocytic Ca²⁺ levels and gliotransmission^{28, 62, 72}. While the mechanistic link between astrocytic Ca²⁺ and gliotransmitter release has not to date been fully characterized, it is clear that the process is distinctly different from presynaptic neurotransmitter release in neurons. Nonetheless, astrocytes do exhibit diverse Ca²⁺ activities in distinctive sub-

compartments^{73–75}. The result of this activity may be the release of a variety of transmitters via several different mechanisms^{23, 70, 76, 77}. Of note, a single astrocyte can release different types of gliotransmitters, which cause multi-phasic synaptic responses in nearby neurons⁷⁸. Furthermore, the type of released gliotransmitters is correlated with the duration and frequency of neural activities nearby, suggesting that astrocytes can sense and process spatiotemporal information from neurons⁷⁸.

Reciprocal communication between astrocytes and neurons

A single mature astrocyte can contact up to 140,000 synapses in rodents, and upwards of 2 million in humans^{7, 79}. Of note, the enwrapment of synapses by astrocytes is crucial for a range of astrocyte functions, including the sensing and modulation of neuronal activity, preventing neurotransmitter spillover from synapses, as well as the stabilization of synapses themselves. Furthermore, an individual astrocyte can contact synapses from multiple, different neurons, resulting in a term now coined “astrocyte-defined synaptic islands”⁸⁰. Neurons within a synaptic island spread out up to 200 μm ⁸¹, thereby poisoning astrocytes to potentially contribute to the activity of neuronal ensembles.

Glutamate is an example of a neurotransmitter through which astrocytes and neurons communicate bidirectionally. Elevation of astrocytic Ca^{2+} levels can result in a SNARE protein-dependent vesicular release of glutamate⁸². Independent of vesicular release, glutamate can diffuse out from astrocytes via nonspecific ion channels upon activation of G-protein-signaling^{83, 84}, or be transported out of astrocytes via a cystine-glutamate exchanger⁸⁵. Nonetheless, astrocyte-released glutamate activates extrasynaptic GluN2B-containing NMDA receptors (NMDARs) on neurons, resulting in slow inward currents that depolarize these neurons synchronously^{86, 87}. Astrocyte-released glutamate may also activate pre- and postsynaptic glutamatergic receptors, influencing both presynaptic release and postsynaptic responsiveness^{88, 89}. Conversely, astrocytes respond to neuronal-released glutamate via metabotropic glutamate receptors (mGluRs) or ionotropic glutamate receptors. Among the eight known mGluRs, mGluR3 and 5 have been detected in astrocytes^{90, 91}. mGluR3, which is $G_{i/o}$ -coupled, is expressed predominantly in adult astrocytes and is presumed to inhibit adenylyl cyclase with no direct influence on Ca^{2+} activity. Indeed, little to no Ca^{2+} activity is recorded in cortical or hippocampal astrocytes in responses to an mGluR3 agonist^{92, 93}. However, a robust Ca^{2+} signal is detected in striatal astrocytes⁹³.

In contrast, activation of mGluR5 increases Ca^{2+} levels in astrocytes through the $G_{q/11}$ -linked activation of PLC β -IP3R2-PKC or other signaling pathways^{94–96}. There has been an interesting debate related to the existence and functional importance of mGluR5 in mature astrocytes. Using immunostaining combined with electron microscopy, it was demonstrated in the hippocampus and cortex that astrocytic expression of mGluR5 decreases to very low levels after development⁹⁷. In line with this result, mGluR5 agonists fail to induce Ca^{2+} elevations in adult astrocytes within these brain regions^{93, 97}. These results suggest that mGluR5-mediated astrocytic responses decline substantially after development. However, albeit at very low levels, mGluR5 is detected in other preparations, raising the possibility that mGluR5 activity is still present, particularly in distal processes where Ca^{2+} signals may be too weak to be detected based on traditional bulk-loaded fluorescent Ca^{2+}

dyes. Highlighting astrocyte heterogeneity and regional specificity, it is also important to note that expression of mGluR5 in astrocytes differs substantially among different brain regions⁹³. Indeed, in the NAc of 2–6 weeks old mice, activation of mGluR5 initiates Ca²⁺ oscillations in astrocytes⁹⁵. In addiction-oriented studies, administration of mGluR5 antagonists, especially via intra-NAc infusion, decreases cocaine taking during cocaine self-administration and cocaine seeking after drug withdrawal^{98–101}. It is important to determine whether these behavioral responses to mGluR5 manipulations are mediated by mGluR5 located in astrocytes or neurons.

Another molecule that may act as both a neuro- and gliotransmitter is ATP¹⁰². ATP can be released from astrocytes through a Ca²⁺-dependent mechanism involving SNARE proteins^{103, 104}. In these experiments, a variety of stimulations that induce astrocytic Ca²⁺ waves can trigger ATP release^{65, 105, 106}. In the cerebral cortex, synaptically-released glutamate induces astrocytic ATP release via activation of astrocytic NMDARs, presumably also involving Ca²⁺-mediated processes^{107, 108}. As well, astrocytic release of ATP is mediated via mechanisms independent of Ca²⁺ or SNARE proteins^{109, 110}. Astrocytes respond to neuronal or astrocytic release of ATP through several purinergic P2 class ATP receptors (Figure 1). Both *in vitro* and *in vivo* data demonstrate that astrocyte-released ATP induces Ca²⁺ waves in nearby astrocytes^{106, 111}. Through ATP-purinergic signaling, Ca²⁺ waves initiated in one astrocyte can propagate to nearby astrocytes^{111, 112} in a regenerative and neural activity-independent manner¹¹³. P2Y1 receptor-mediated ATP signaling has been shown to induce glutamate release from astrocytes¹¹⁴.

Once released, ATP is quickly (within 200 ms) hydrolyzed to adenosine by ectonucleotidases within the extracellular matrix¹¹⁵. Thus, in addition to ATP receptors, ATP-derived adenosine influences neural activities by binding neuronal A1 receptors (A1Rs) (Figure 1). Through A1Rs, adenosine originating from astrocytes enhances basal glutamatergic synaptic transmission and reduces the magnitude of LTP⁶⁵, effects that might be related to the action of astrocytic adenosine on synaptic expression of NMDARs¹¹⁶.

Dopamine is a neuromodulator that regulates synaptic and circuit activities and has been implicated in many psychiatric disorders^{117–120}. D1 and D2 dopamine receptors (D1Rs and D2Rs), which are coupled to distinct intracellular signaling cascades¹²¹, are both detected in astrocytes^{122–125}. While activation of D1Rs leads to an elevation of astrocytic levels of Ca²⁺ and activation of cAMP-PKA signaling^{123, 126–129}, the effects of dopamine on astrocytes also appear to be mediated by D2Rs and other mechanisms. Specifically, incubation of cultured astrocytes with dopamine induces stellation of astrocyte processes, which is only partially mediated by cAMP signaling¹³⁰. In hippocampal brain slices, superfusion of dopamine induces a fast onset elevation of astrocytic levels of Ca²⁺, which is followed by a more sustained decrease¹³¹. Application of a mixture of D1R and D2R antagonists blunts these biphasic dopamine-induced effects, while D1R antagonists alone selectively prevent the first phase elevation of astrocytic Ca²⁺ levels, suggesting D2Rs as a key in decreasing astrocytic Ca²⁺ level during the second phase following dopamine¹³¹. Consistent with this interpretation is the finding that application of D2R agonists decreases astrocytic levels of Ca²⁺ in PFC slices¹²⁴. Dopamine also influences astrocytes in the ventral tegmental area (VTA) and NAc, work discussed in the next section.

In addition to responding to dopamine, astrocytes regulate extracellular levels of dopamine via astrocytic dopamine, norepinephrine, and other transporters^{132–135}. After reuptake, dopamine in astrocytes is metabolized by monoamine oxidase, and the resulting oxygen species increase intracellular levels of Ca^{2+} ¹³⁶, thus providing a D1R- and D2R-independent mechanism underlying dopamine-mediated regulation of astrocyte Ca^{2+} activity. Interestingly, vesicular monoamine transporter 2 is detected in astrocytes, and genetic deletion of VMAT2 in PFC astrocytes results in impaired LTP and behavior^{137, 138}, suggesting the possibility that dopamine can be packaged for vesicular release in astrocytes. If this or similar astrocytic dopamine release exists, which requires confirmation, astrocytes may serve a noncanonical source of dopaminergic signaling.

Astrocytes regulate synaptic plasticity and synaptogenesis

Experience-dependent synaptic plasticity serves a key cellular mechanism for learning and memory^{139–143}. In the classical Hebbian model, manipulation of pre- and postsynaptic activities alone is sufficient to induce many forms of LTP or LTD at glutamatergic synapses. However, more recent evidence suggests that astrocytes are also integral to some forms of LTP and LTD. In response to LTP induction, the astrocytic coverage of synapses increases¹⁴⁴. This morphological change may effectively increase astrocyte-mediated regulation of synaptic transmission via stabilization of synapses themselves as well as via preventing neurotransmitter synaptic spillover. Additionally, direct astrocytic stimulation⁶⁶ or elevation of astrocytic Ca^{2+} levels¹⁴⁵ transiently increases presynaptic release probability at hippocampal glutamatergic synapses. Furthermore, when astrocytic Ca^{2+} elevation is paired with postsynaptic depolarization, the increased presynaptic release probability becomes persistent, resulting in an LTP-like effect at these synapses¹⁴⁵. These results raise the important possibility that, without presynaptic conditioning, coincidental activities of postsynaptic neurons and their neighboring astrocytes are sufficient to induce synaptic plasticity. Correspondingly, electrophysiological or pharmacological suppression of astrocytic activities impairs the induction of the classic NMDAR-dependent hippocampal LTP^{146, 147}. In a form of spike timing-dependent LTD (t-LTD), in which coincident postsynaptic release of endocannabinoids (eCBs) and presynaptic activation of NMDARs are essential, astrocytes serve as a lynchpin; postsynaptically-released eCBs activate CB1 receptors on adjacent astrocytes, which, in turn, release glutamate to activate presynaptic NMDARs, accomplishing the induction process¹⁴⁸. Furthermore, adenosine signaling originating from astrocyte-released ATP coordinates adjacent synapses such that both monosynaptic LTP and heterosynaptic LTD are induced simultaneously⁶⁵. These findings describe an active role of astrocytes in the induction and possibly also maintenance of Hebbian plasticity.

Synaptogenesis requires participation of both pre- and postsynaptic neurons^{149, 150}, with increasing evidence suggesting that this process also requires the participation of astrocytes¹⁵¹. During development, astrocytes and neurons share the same precursor cells, but astrogenesis occurs in postnatal stages, after the bulk of neurogenesis is accomplished^{152–154}. Importantly, robust synaptogenesis only occurs after the emergence of astrocytes, particularly during the first 2 to 3 postnatal weeks in rodents, which is a major maturation window for astrocytes^{151, 155}. Evidence suggests that astrocytes actively

and directly contribute to both the structural and functional aspects of synaptogenesis and synapse maturation. Most prominently studied are synaptogenic factors derived from astrocytes. Neuronal cultures devoid of astrocytes form far fewer synapses than in neuron-astrocyte co-cultures¹⁵⁶, and those synapses appear to be functionally immature¹⁵⁷. Treating these astrocyte-free cultures with astrocyte-conditioned medium induces the formation of new synapses, suggesting that astrocytes secrete soluble factors to promote synaptogenesis^{158–162}.

This review focuses on one set of soluble astrocyte-derived factors, thrombospondins (TSPs). For a comprehensive review of astrocytes and synaptogenesis and maturation, we refer the reader to a recent review¹⁵⁵. Through activation of their neuronally-located target, $\alpha 2\delta-1$, astrocyte-secreted TSPs promote synaptogenesis during development^{158, 163}. TSPs are multimeric, multidomain glycoproteins that, by binding to proteases, cytokines, growth factors, and other components of the extracellular matrix, facilitate cell attachment, migration, cytoskeletal dynamics, and angiogenesis^{164, 165}. TSP-induced synapses appear structurally normal—with pre- and postsynaptic specializations, normal amounts of presynaptically-docked vesicles, and regular dimensions of postsynaptic densities—but are postsynaptically “silent” in that they do not contain functionally stable AMPA glutamate receptors (AMPARs)¹⁵⁸. This AMPAR-labile feature is consistent with immature, AMPAR-silent glutamatergic synapses found in the developing brain, some of which subsequently mature and become fully functional by recruiting AMPARs^{166–169}. Of note, synapses generated in astrocyte-present neuronal cultures do express stable postsynaptic AMPARs, highlighting that astrocyte-derived signaling molecules other than TSPs are involved in synapse maturation¹⁵⁸.

$\alpha 2\delta-1$, described originally as an auxiliary subunit of voltage-gated calcium channels (VGCCs) located at both axons and dendrites^{170–172}, has been identified as one of the key neuronal targets for TSP-mediated synaptogenesis. Overexpression of $\alpha 2\delta-1$ augments TSP-induced synaptogenesis, while expression of a dominant-negative form of $\alpha 2\delta-1$ impairs TSP-induced synaptogenesis¹⁶³. Gabapentin, an $\alpha 2\delta-1$ antagonist that is used clinically to treat chronic pain, binds to the $\alpha 2$ domain of $\alpha 2\delta-1$, the same binding site as TSPs^{173, 174}, but the binding does not alter Ca^{2+} currents conducted by VGCCs¹⁷⁵. Administration of gabapentin prevents astrocyte- and TSP-induced synaptogenesis, identifying $\alpha 2\delta-1$ as an essential component in this developmental synaptogenic signaling¹⁶³. However, despite its intimate relationship with VGCCs, $\alpha 2\delta-1$ -mediated synaptogenesis is independent of VGCC function¹⁶³. The key cellular steps from TSP- $\alpha 2\delta-1$ binding to synapse formation have not been elucidated¹⁷⁶. The small GTPase Rac1 has been implicated in this process¹⁷⁷, and Rac1 is also known to influence synapse plasticity following cocaine exposure^{178, 179}. In addition to $\alpha 2\delta-1$, TSPs also interact with other synaptic proteins, such as neuroligins, to refine the synaptogenic process¹⁸⁰. Beyond TSPs, astrocytes secrete hevin and sparc, which, among other molecules, facilitate synaptogenesis as well^{160, 181, 182}. These and other results depict a critical role of astrocytes in synapse formation during development.

Cooperatively operating with synaptogenesis in forming new circuits, synapse elimination is essential for the refinement of neural circuits in the developing brain as well as remodeling

of neural circuits and the turnover of synapses in the adult brain. Similar to microglia, astrocytes can engulf large synaptic components (i.e., synaptosomes), and direct them to lysosomes for ultimate degradation^{183, 184}. A key form of such astrocyte-mediated synapse elimination is mediated by astrocyte phagocytic receptors, such MERTK (a type of protein tyrosine kinase) and MEGF10 (an epidermal growth factor-domain family protein), which can sense “eat-me” signals (e.g., phosphatidylserine) that are presented by targeted debris to execute the engulfment^{185–187}. As such, this form of phagocytosis is not random, but, rather, driven by neuronal activities and mediated by precise signaling exchange between neurons and astrocytes. Astrocytes also release cytokines, such as TGF- β , which can tag synapses for microglia-mediated synapse elimination^{188, 189}. Detailed discussion of these and other forms of astrocyte-mediated synapse elimination can be found in several excellent reviews^{183, 184, 190}.

Astrocytes in neural adaptations after exposure to drugs of abuse

Astrocytes in the VTA-NAc reward circuit respond directly to dopamine

Dopamine’s involvement in the reward pathway and in substance abuse and other psychiatric disorders is well documented^{117–120, 191–205}. Exposure to natural rewards or to drugs of abuse like cocaine induces bursting activity of VTA dopamine neurons, leading to a transient increase in extracellular dopamine levels in the NAc and other limbic forebrain regions^{191, 192}. In contrast, withdrawal from cocaine or other drugs of abuse decreases extracellular dopamine levels in these brain regions^{196–199}, whereas re-exposure to the drug or to drug-predicting cues after drug withdrawal increases such levels^{200–205}. It is noteworthy, as mentioned above and detailed below, that astrocytes in several brain regions associated with the reward circuitry respond directly to the dynamics of extracellular dopamine.

In vivo optogenetic stimulation of VTA dopaminergic nerve terminals within the NAc induces dopamine release and, concomitantly, increases Ca²⁺ activity in roughly half of NAc astrocytes, lasting for several seconds²⁰⁶. This dopamine-elicited astrocytic response appears to be mediated at least in part by D1Rs on astrocytes and, potentially through ATP/adenosine signaling, contributes to transient inhibition of nearby glutamatergic synaptic transmission²⁰⁶. In concert with these results, superfusion of cocaine, which elevates extracellular dopamine levels in NAc slices^{207, 208}, increases both the frequency and total number of astrocytic Ca²⁺ transients²⁰⁹. Paradoxically, AAV-mediated deletion of D1Rs in NAc astrocytes increases basal Ca²⁺ activity in this brain region²⁰⁶. In the VTA and surrounding ventral midbrain areas, activation of D2Rs on astrocytes revealed a blunted Ca²⁺ response²¹⁰. These findings, coupled with distinct responses of astrocytes in hippocampus and PFC to dopamine (see above), again highlight the regional heterogeneity of astrocytes and implicate a far more complex dopamine-mediated regulation of astrocytes than previously understood.

Astrocytes in the NAc

Transcriptomic analyses²¹¹ reveal that striatal astrocytes (encompassing NAc and dorsal striatum) express high levels of K⁺ channels, setting their equilibrium membrane

potential at ~ -85 mV, which is more hyperpolarized than astrocytes in many other brain regions^{212, 213}. Striatal astrocytes also express high levels of gap-junction proteins, allowing for synchronized activities among connected astrocytes⁹³. Interestingly, this astrocytic syncytium can spread across brain regions such that a dye infused into a single striatal astrocyte can eventually diffuse into cortical astrocytes²¹⁴. Basal spontaneous Ca^{2+} activities in striatal astrocytes are insensitive to TTX, suggesting that they are relatively independent of ongoing neuronal activities⁹³.

Striatal GABAergic medium spiny neurons (MSNs) comprise >90% of the local neuronal population and represent the sole projection neurons of this region²¹⁵. MSNs can be divided into two subpopulations: one that expresses predominantly D1Rs and the neuropeptides dynorphin and substance P, and another that expresses D2Rs and enkephalin²¹⁶. In the dorsal striatum, subpopulations of astrocytes show selective responsivity to the activity of either D1 or D2 MSNs²¹⁷. Such cell-type specific neuron-astrocyte interactions may contribute to the heterogeneous responses of D1R versus D2R NAc MSNs to cocaine, such as selective generation of silent synapses in D1R MSNs after noncontingent cocaine exposure²¹⁸. Compared to noncontingent procedures, astrocytic adaptations to contingent (volitional) exposure to cocaine are likely more complex than previously believed given that astrocytes respond both to neuronal activity and directly to dopamine. Much of this work to date has focused on dorsal striatum, with studies of NAc specifically now being a high priority.

Extinction is a training procedure in rodent models of drug relapse, in which the learned drug taking and seeking are diminished in the absence of anticipated reinforcement. Extinction requires new reinforcement learning that involves remodeling of glutamatergic transmission in the NAc^{219–223}. After extinction of cocaine self-administration, NAc expression of glial fibrillary acidic protein (GFAP) as well as the overall surface area and volume of astrocytes are decreased, effects accompanied by reduced co-localization of astrocyte processes with the presynaptic nerve terminal marker, synapsin-1²²⁴. Importantly, without extinction training, the synapse-astrocyte proximity remains largely unchanged in the NAc after cocaine self-administration, selectively linking this form of astrocytic adaptation to extinction²²⁵. Furthermore, this extinction-related astrocytic adaptation is only detected in the NAc and not in the PFC or basolateral amygdala (BLA), indicating the unique response of NAc astrocytes in extinction learning²²⁵. Similar extinction-related changes in NAc astrocytes are also observed after extinction from methamphetamine²²⁶ or heroin²²⁷ self-administration. Importantly, re-exposure to heroin-associated cues after extinction transiently restores the reduced synapse-astrocyte proximity²²⁷, suggesting a dynamic role of NAc astrocytes in response to cue-induced drug seeking after drug extinction. DREADD-mediated activation of NAc astrocytes after drug extinction decreases subsequent cue-induced cocaine²²⁸ and methamphetamine²²⁶ seeking, possibly through restoring astrocyte-mediated glutamate homeostasis in the NAc (see below).

Unlike psychostimulants, opioids initiate their primary pharmacological effects by activating μ opioid receptors (MORs)²²⁹. NAc astrocytes express MORs²³⁰ that can be activated upon opioid administration. In acutely prepared NAc slices, superfusion of morphine increases astrocytic Ca^{2+} levels through IP3R2-mediated release from intracellular stores²³¹.

Activation of MORs induces astrocytic glutamate release, which, in turn, induces NMDAR-mediated slow inward currents in nearby neurons²³¹. Considering that an individual striatal astrocyte contacts ~20 neuronal somas⁹³, morphine-induced slow inward currents may be present throughout NAc MSNs. In drug-naïve animals, intra-NAc infusion of astrocyte-conditioned medium, which contains a variety of soluble astrocytic factors, acutely enhances the rewarding effect of morphine²³². Furthermore, intra-NAc infusion of such media from morphine-pretreated astrocytes results in a stronger preference for drug-associated environments than infusions of media from astrocytes without morphine pretreatment²³². Albeit preliminary, these results suggest a clear link between NAc astrocytes and opioid-induced behaviors.

Astrocytes regulate glutamate homeostasis

Cortical glutamatergic projections to the NAc regulate general reward seeking under physiological conditions^{233–235}. Proper functioning of this projection is maintained, in part, by homeostatic regulation of glutamate at both synaptic and extrasynaptic sites. Disruption to this homeostasis during drug experience contributes to drug seeking and relapse²³⁶.

A key element to this disruption is GLT-1, a glutamate transporter expressed in perisynaptic astroglial processes that contributes to >90% of glutamate reuptake^{21, 22, 237–242}. Chronic exposure to either psychostimulants or opioids reduces the expression of GLT-1 in the NAc at both the mRNA and protein levels^{243, 244}. Furthermore, chronic drug exposure reduces the overlap of perisynaptic astroglial processes with synaptic markers, suggesting decreased astrocytic insulation of synapses^{224–227}. Both of these changes impair the clearance of synaptic glutamate, facilitating spill-over to perisynaptic regions, and establishing an inter-synaptic crosstalk^{245–248} (Figure 2). Glutamatergic synaptic transmission within the NAc is pathophysiologically upregulated after withdrawal from many classes of drugs of abuse^{233, 249–251}. The diminished reuptake of glutamate through GLT-1 may exacerbate this pathophysiology. Moreover, glutamate spillover can activate glutamatergic receptors such as NMDARs and mGluRs in neighboring synapses^{146, 252–254}, resulting in nonspecific neuronal activity not observed in drug-naïve subjects. Indeed, administration of mGluR5 antagonists decreases cocaine seeking after drug withdrawal^{98–101}. Multiple pharmacological approaches that normalize GLT-1 function in cocaine-exposed animals have proven useful in reducing cue-induced reinstatement of cocaine seeking in animal models^{243, 255, 256}, raising the hope for treating drug relapse by targeting astrocyte-maintained glutamate homeostasis.

While astrocytic GLT-1 regulates synaptically-released glutamate, the cystine/glutamate (xCT) exchanger in astrocytes maintains ambient levels of glutamate within the extracellular space²⁵⁷. xCT functions via the exchange of one extracellular cystine for one intracellular glutamate²⁵⁸. xCT therefore contributes to the extracellular tone of glutamate, which, in turn, modulates activity of presynaptic group II mGluRs (e.g., mGluR2/3) that control levels of synaptically-released glutamate²⁵⁷. This xCT-mediated regulation of glutamate is impaired after drug experience²³⁶. After withdrawal from cocaine or nicotine self-administration, levels of xCT in the NAc core are reduced, contributing to the drug withdrawal-associated reduction of extracellular glutamate^{85, 255, 259–261}. A basal level

of extracellular glutamate is needed for tonic activation of presynaptic group II mGluRs (e.g., mGluR2/3) to limit glutamate release from presynaptic terminals²⁶². As such, decreased levels of ambient glutamate compromises this inhibitory control of presynaptic glutamate release and promotes glutamate overflow, a cellular maladaptation that contributes to drug seeking²⁶³ (Figure 2). In fact, astrocytic h3Mdq-DREADD-mediated reductions cocaine seeking (see below) are ameliorated with concomitant administration of mGluR2/3 antagonists²²⁸.

A therapeutic approach to targeting xCT has also been tested with the use of N-acetylcysteine, a cysteine prodrug and substrate of xCT. Administration of N-acetylcysteine restores the compromised function of xCT following chronic cocaine exposure and decreases drug- and cue-induced relapse to cocaine seeking²⁵⁹. N-acetylcysteine also restores GLT-1 expression in the NAc and is thought to ameliorate extrasynaptic glutamate spillover following cocaine extinction and reinstatement²⁴³. This might be due to the restoration of plasticity at PFC-to-NAc synapses known to be impaired after cocaine self-administration²⁶⁴. Furthermore, after withdrawal from cocaine self-administration, administration of N-acetylcysteine enhances the sensitivity of rats to the punishment that induces extinction of drug seeking, suggesting multi-angled anti-relapse effects of N-acetylcysteine²⁶⁵. In early clinical studies, administration of N-acetylcysteine reduces cocaine craving and thus decreases the risk of relapse in individuals during drug abstinence²⁶⁶. Beyond cocaine, N-acetylcysteine also reduces the number of cigarettes consumed in active smokers²⁶¹ and exhibits beneficial effects on PTSD patients^{267, 268}.

As discussed above, by decreasing the function or protein expression of GLT-1 and xCT, cocaine experience simultaneously increases spillover of synaptically-released glutamate and decreases ambient glutamatergic tone in the NAc, both of which promote cocaine seeking²⁴³. This line of results raises several interesting considerations. For example, mGluR activity at cortical glutamatergic projection terminals versus dopaminergic projection terminals are linked to the effects of GLT-1 versus xCT, respectively^{257, 263, 269, 270}. If both of these effects are mediated by the same astrocytes, the astrocyte microdomains or processes that are close to glutamatergic versus dopaminergic synapses are likely to operate independently. This is not surprising, as such compartmentalized responses of astrocytes to different forms of stimulation has been demonstrated^{271, 272}. However, this potentially domain-oriented functioning of astrocytes indicates that a more nuanced investigation of astrocyte-neuron partnership is needed. Furthermore, decreased function of GLT-1 after extinction of cocaine self-administration increases the likelihood of glutamate spillover, resulting in increases of glutamate in neuropil. This effect may somewhat compensate for the reduction of ambient glutamate in the NAc upon diminished expression of xCT. As such, homeostatic mechanisms may exist in NAc astrocytes^{43, 273}, functioning in part through GLT-1 and xCT to balance synaptic versus ambient glutamate. Emerging evidence suggests that such homeostatic regulation or dysregulation between GLT-1 and xCT may be organized by cascades of epigenetic changes following extinction from cocaine self-administration²⁷⁴.

Astrocyte-mediated synaptogenesis

The neural rejuvenation hypothesis of drug addiction²⁷⁵ proposes that “repeated exposure to drugs of abuse induces plasticity mechanisms that are normally associated with brain development within the brain’s reward circuitry, which mediate the highly efficient and unusually stable memory abnormalities that characterize addiction.” Astrocytes promote synapse formation during development, but these astrocyte-mediated synaptogenic mechanisms become much less active after postnatal week 3 in rodents when the major wave of synapse formation is accomplished²⁷⁶. Cocaine experience generates AMPAR-silent synapses in the adult NAc, and these synapses exhibit several features consistent with nascent glutamatergic synapses observed during development^{277, 278}. Recent results demonstrate that cocaine-induced generation of silent synapses in the adult NAc is mediated, in part, by an astrocyte-derived developmental synaptogenic mechanism, namely, TSP- $\alpha 2\delta-1$ signaling²⁰⁹. TSPs are abundantly expressed during early developmental stages, but decline to low levels in most brain regions during adulthood²⁷⁹. Albeit at low levels, basal expression of TSP1/2 is detected in the adult NAc, where neuronal expression of $\alpha 2\delta-1$ remains robust at this time point^{209, 280}. In acutely prepared NAc slices, superfusion of cocaine increases Ca^{2+} -mediated activities in astrocytes²⁰⁹. Within the dorsal striatum, DREADD-mediated activation of $G_{i/o}$ -coupled GPCRs increases Ca^{2+} activity in astrocytes with the subsequent release of TSP1²⁸¹. While the underlying mechanisms remain largely unclear, these studies suggest that the cocaine-induced release of TSP2 from astrocytes may reflect a direct effect of dopamine on astrocytic GPCR signaling and downstream elevations in intracellular Ca^{2+} levels. Administration of gabapentin, which as noted earlier disrupts the binding of TSP2 to $\alpha 2\delta-1$ ^{163, 177}, prevents cocaine-induced generation of silent synapses and cocaine-induced spinogenesis in the NAc, suggesting the involvement of TSP- $\alpha 2\delta-1$ signaling²⁰⁹. Additionally, selective knockdown of either $\alpha 2\delta-1$ in neurons or TSP2 in astrocytes prevents cocaine-induced generation of silent synapses in the NAc, indicating that astrocyte-derived TSP2, and $\alpha 2\delta-1$ on MSNs, form a synaptogenic signal to generate silent synapses *de novo* in response to cocaine²⁰⁹, by analogy to what is observed during development^{158, 163} (Figure 3). These results—in line with the neural rejuvenation hypothesis—suggest that cocaine experience utilizes astrocyte-mediated synaptogenic mechanisms to “re-develop” NAc circuits, potentially generating new connectivity patterns that support cocaine-associated memories.

After drug withdrawal, some cocaine-generated silent synapses mature by recruiting AMPARs, which may stabilize the remodeled NAc circuits and result in the consolidation of cocaine memories^{179, 218, 235, 282–284}. These synapses appear to remain dynamic, as retrieval-induced destabilization and reconsolidation of cue-associated cocaine memories are influenced by the re-silencing and re-maturation of these synapses, respectively, following re-exposure to cocaine-associated cues^{179, 285}. Thus, the generation of silent synapses is a key mechanism through which astrocytes can influence NAc circuits to promote cue-induced cocaine seeking. It is therefore not surprising that selectively disrupting astrocytic TSP- $\alpha 2\delta-1$ -signaling during cocaine self-administration, preventing cocaine-induced generation of silent synapses and therefore silent synapse-mediated NAc remodeling, results in both decreased cue-induced cocaine seeking after cocaine withdrawal and decreased cue-induced reinstatement of cocaine seeking after cocaine extinction²⁰⁹. Importantly, intra-

NAc disruption of TSP- α 2 δ -1-signaling does not prevent animals from acquiring operant responding to cocaine in the first place²⁰⁹, indicating that astrocyte-mediated synaptogenesis in the NAc is selectively involved in the formation of cue-associated cocaine memories without affecting basic instrumental learning.

In addition to synaptogenesis during cocaine exposure, TSP- α 2 δ -1 signaling may contribute to withdrawal-associated neural adaptations. Selectively inhibiting NAc α 2 δ -1 only after extinction from cocaine self-administration decreases cocaine priming-induced reinstatement of drug seeking²⁸⁰. This finding indicates that TSP- α 2 δ -1 signaling and presumably other astrocytic mechanisms are critically involved in neural adaptations that mediate multiple phases of drug-associated behaviors. Furthermore, chemogenetically upregulating NAc astrocyte activity after drug extinction acutely decreases subsequent cocaine²²⁸ and methamphetamine²²⁶ seeking, suggesting that, in addition to adaptive changes, NAc astrocytes also influence ongoing NAc circuit function that controls drug-seeking behaviors.

Concluding Remarks

Astrocytes are increasingly recognized as key players in brain function under physiological and pathophysiological conditions. We highlight some recently identified mechanisms through which astrocytes regulate synapses and neural circuits to promote addiction-related behaviors. Additionally, in cocaine-trained animals, manipulating astrocytes prevents drug-induced neural adaptations and ameliorates addiction-related behavioral abnormalities. These findings not only establish astrocytes as promising cellular targets to explore novel mechanisms underlying drug addiction, but also specify several future directions. First, a wide range of astrocytic substrates responds to neural activities and external stimuli. GLT-1 and xCT likely represent the tip of the iceberg of astrocytic substrates that undergo adaptive changes following repeated drug experience. It is important for future studies to systematically screen and identify key astrocytic substrates that are changed by drug experience to influence behaviors. Second, while this manuscript focuses on the NAc, many other brain regions are also critically involved in drug-induced behaviors. For example, similar to the NAc, cocaine self-administration increases the density of dendritic spines expressed by pyramidal neurons in the prefrontal cortex (PFC), suggesting a similar synaptogenic process^{286, 287}. However, astrocytes in the NAc and PFC are highly heterogeneous, and their differential responses to cocaine are only beginning to be elucidated²²⁵. It is critical for future studies to characterize such regional specificity, neuronal-partner selectivity, and domain-specific specializations, and how these features influence drug-induced alterations. Third, drug exposure, withdrawal, extinction, reinstatement, and other related conditions constitute different aspects of the drug-related experience that contribute differentially to the addicted state. Astrocytes influence both synaptogenesis during drug exposure and dysregulation of glutamate homeostasis after drug withdrawal, indicating a phasic involvement of astrocytes. It is important to determine the astrocytic contributions across these phases to influence neural and behavioral consequences. The role of astrocytes in addiction is likely defined both by the direct actions of drugs of abuse on astrocytes as well as by astrocytic dysregulation that occurs as a consequence of dynamic neuron-astrocyte interactions during drug withdrawal, abstinence,

and relapse. These divergent mechanisms underscore the need to elucidate the increasingly complex role of astrocytes in the brain under normal and pathophysiological conditions. Pursuing these and other questions will provide a new angle to understanding the cellular and circuit mechanisms underlying drug-induced behavioral abnormalities.

Acknowledgements:

Preparation of this review was supported by NIH grants R01DA014133 (EJN), R01DA040620 (EJN, YD), R21DA047861 (YD), R37DA023206 (YD) and R21DA051010 (YD).

References

1. Pfrieger FW, Barres BA. What the fly's glia tell the fly's brain. *Cell* 1995; 83(5): 671–674. [PubMed: 8521482]
2. Vasile F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain. *Brain Struct Funct* 2017; 222(5): 2017–2029. [PubMed: 28280934]
3. Bass NH, Hess HH, Pope A, Thalheimer C. Quantitative cytoarchitectonic distribution of neurons, glia, and DNA in rat cerebral cortex. *The Journal of comparative neurology* 1971; 143(4): 481–490. [PubMed: 4945394]
4. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. *Neurobiol Aging* 2008; 29(11): 1754–1762. [PubMed: 17544173]
5. Oikonomou G, Shaham S. The glia of *Caenorhabditis elegans*. *Glia* 2011; 59(9): 1253–1263. [PubMed: 21732423]
6. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F et al. Uniquely hominid features of adult human astrocytes. *J Neurosci* 2009; 29(10): 3276–3287. [PubMed: 19279265]
7. Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. *Trends Neurosci* 2006; 29(10): 547–553. [PubMed: 16938356]
8. Han X, Chen M, Wang F, Windrem M, Wang S, Shanz S et al. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. *Cell Stem Cell* 2013; 12(3): 342–353. [PubMed: 23472873]
9. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. *Trends Neurosci* 2009; 32(8): 421–431. [PubMed: 19615761]
10. Perea G, Araque A. Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. *J Neurosci* 2005; 25(9): 2192–2203. [PubMed: 15745945]
11. Perea G, Araque A. Synaptic Information Processing by Astrocytes. In: Haydon PG, Pappas V (eds). *Astrocytes in (Patho)Physiology of the Nervous System*. Springer US: Boston, MA, 2009, pp 287–300.
12. Santello M, Toni N, Volterra A. Astrocyte function from information processing to cognition and cognitive impairment. *Nat Neurosci* 2019; 22(2): 154–166. [PubMed: 30664773]
13. Zhang Y, Barres BA. A smarter mouse with human astrocytes. *Bioessays* 2013; 35(10): 876–880. [PubMed: 23897758]
14. Spacek J. Three-dimensional analysis of dendritic spines. III. Glial sheath. *Anat Embryol (Berl)* 1985; 171(2): 245–252. [PubMed: 3985373]
15. Oceau JC, Chai H, Jiang R, Bonanno SL, Martin KC, Khakh BS. An Optical Neuron-Astrocyte Proximity Assay at Synaptic Distance Scales. *Neuron* 2018; 98(1): 49–66 e49. [PubMed: 29621490]
16. Kikuchi T, Gonzalez-Soriano J, Kastanauskaite A, Benavides-Piccione R, Merchan-Perez A, DeFelipe J et al. Volume Electron Microscopy Study of the Relationship Between Synapses and Astrocytes in the Developing Rat Somatosensory Cortex. *Cereb Cortex* 2020; 30(6): 3800–3819. [PubMed: 31989178]
17. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. *Prog Neurobiol* 1997; 51(4): 439–455. [PubMed: 9106901]

18. Biber K, Laurie DJ, Berthele A, Sommer B, Tolle TR, Gebicke-Harter PJ et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. *J Neurochem* 1999; 72(4): 1671–1680. [PubMed: 10098876]
19. Velez-Fort M, Audinat E, Angulo MC. Central role of GABA in neuron-glia interactions. *Neuroscientist* 2012; 18(3): 237–250. [PubMed: 21609943]
20. Ribak CE, Tong WM, Brecha NC. GABA plasma membrane transporters, GAT-1 and GAT-3, display different distributions in the rat hippocampus. *The Journal of comparative neurology* 1996; 367(4): 595–606. [PubMed: 8731228]
21. Schousboe A. Transport and metabolism of glutamate and GABA in neurons and glial cells. *Int Rev Neurobiol* 1981; 22: 1–45. [PubMed: 6115823]
22. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D et al. Localization of neuronal and glial glutamate transporters. *Neuron* 1994; 13(3): 713–725. [PubMed: 7917301]
23. Szatkowski M, Barbour B, Attwell D. Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. *Nature* 1990; 348(6300): 443–446. [PubMed: 2247147]
24. Cotrina ML, Lin JH, Alves-Rodrigues A, Liu S, Li J, Azmi-Ghadimi H et al. Connexins regulate calcium signaling by controlling ATP release. *Proc Natl Acad Sci U S A* 1998; 95(26): 15735–15740. [PubMed: 9861039]
25. Warr O, Takahashi M, Attwell D. Modulation of extracellular glutamate concentration in rat brain slices by cystine-glutamate exchange. *J Physiol* 1999; 514 (Pt 3): 783–793. [PubMed: 9882750]
26. Lutter D, Ullrich F, Lueck JC, Kempa S, Jentsch TJ. Selective transport of neurotransmitters and modulators by distinct volume-regulated LRRC8 anion channels. *J Cell Sci* 2017; 130(6): 1122–1133. [PubMed: 28193731]
27. Bezzi P, Gundersen V, Galbete JL, Seifert G, Steinhauser C, Pilati E et al. Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. *Nat Neurosci* 2004; 7(6): 613–620. [PubMed: 15156145]
28. Fiacco TA, McCarthy KD. Multiple Lines of Evidence Indicate That Gliotransmission Does Not Occur under Physiological Conditions. *J Neurosci* 2018; 38(1): 3–13. [PubMed: 29298904]
29. Savtchouk I, Volterra A. Gliotransmission: Beyond Black-and-White. *J Neurosci* 2018; 38(1): 14–25. [PubMed: 29298905]
30. Schwarz Y, Zhao N, Kirchoff F, Bruns D. Astrocytes control synaptic strength by two distinct v-SNARE-dependent release pathways. *Nat Neurosci* 2017; 20(11): 1529–1539. [PubMed: 28945220]
31. Navarrete M, Cuartero MI, Palenzuela R, Draffin JE, Konomi A, Serra I et al. Astrocytic p38alpha MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory. *Nat Commun* 2019; 10(1): 2968. [PubMed: 31273206]
32. Takata-Tsuji F, Chounlamountri N, Do LD, Philippot C, Novion Ducassou J, Coute Y et al. Microglia modulate gliotransmission through the regulation of VAMP2 proteins in astrocytes. *Glia* 2021; 69(1): 61–72. [PubMed: 32633839]
33. Rajani V, Zhang Y, Jalubula V, Rancic V, SheikhBahaei S, Zwicker JD et al. Release of ATP by pre-Botzinger complex astrocytes contributes to the hypoxic ventilatory response via a Ca(2+)-dependent P2Y1 receptor mechanism. *The Journal of physiology* 2018; 596(15): 3245–3269. [PubMed: 28678385]
34. Angelova PR, Iversen KZ, Teschemacher AG, Kasparov S, Gourine AV, Abramov AY. Signal transduction in astrocytes: Localization and release of inorganic polyphosphate. *Glia* 2018; 66(10): 2126–2136. [PubMed: 30260496]
35. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. *Trends Neurosci* 1999; 22(5): 208–215. [PubMed: 10322493]
36. Haydon PG. GLIA: listening and talking to the synapse. *Nat Rev Neurosci* 2001; 2(3): 185–193. [PubMed: 11256079]
37. Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. *Nat Neurosci* 2015; 18(7): 942–952. [PubMed: 26108722]
38. Wise RA. Dopamine, learning and motivation. *Nat Rev Neurosci* 2004; 5(6): 483–494. [PubMed: 15152198]

39. Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology* 2010; 35(1): 217–238. [PubMed: 19710631]
40. Adinoff B. Neurobiologic processes in drug reward and addiction. *Harv Rev Psychiatry* 2004; 12(6): 305–320. [PubMed: 15764467]
41. Mogenson GJ, Yang CR, Yim CY. Influence of dopamine on limbic inputs to the nucleus accumbens. *Ann N Y Acad Sci* 1988; 537: 86–100. [PubMed: 3059937]
42. Scofield MD. Exploring the Role of Astroglial Glutamate Release and Association With Synapses in Neuronal Function and Behavior. *Biol Psychiatry* 2018; 84(11): 778–786. [PubMed: 29258653]
43. Scofield MD, Kalivas PW. Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis. *Neuroscientist* 2014; 20(6): 610–622. [PubMed: 24496610]
44. Kim R, Healey KL, Sepulveda-Orengo MT, Reissner KJ. Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis. *Progress in neuro-psychopharmacology & biological psychiatry* 2018; 87(Pt A): 126–146. [PubMed: 28989099]
45. Kruyer A, Kalivas PW. Astrocytes as cellular mediators of cue reactivity in addiction. *Current opinion in pharmacology* 2020; 56: 1–6. [PubMed: 32862045]
46. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. *Science* 1990; 247(4941): 470–473. [PubMed: 1967852]
47. Hille B. Ionic channels: molecular pores of excitable membranes. *Harvey Lect* 1986; 82: 47–69. [PubMed: 2452140]
48. Sperlagh B, Heinrich A, Csolle C. P2 receptor-mediated modulation of neurotransmitter release—an update. *Purinergic Signal* 2007; 3(4): 269–284. [PubMed: 18404441]
49. Sharp AH, Nucifora FC Jr., Blondel O, Sheppard CA, Zhang C, Snyder SH et al. Differential cellular expression of isoforms of inositol 1,4,5-triphosphate receptors in neurons and glia in brain. *The Journal of comparative neurology* 1999; 406(2): 207–220. [PubMed: 10096607]
50. Hussl S, Boehm S. Functions of neuronal P2Y receptors. *Pflugers Archiv : European journal of physiology* 2006; 452(5): 538–551. [PubMed: 16691392]
51. Agulhon C, Boyt KM, Xie AX, Friocourt F, Roth BL, McCarthy KD. Modulation of the autonomic nervous system and behaviour by acute glial cell Gq protein-coupled receptor activation in vivo. *The Journal of physiology* 2013; 591(22): 5599–5609. [PubMed: 24042499]
52. Petravic J, Fiacco TA, McCarthy KD. Loss of IP3 receptor-dependent Ca²⁺ increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. *J Neurosci* 2008; 28(19): 4967–4973. [PubMed: 18463250]
53. Verkhratsky A, Rodriguez JJ, Parpura V. Calcium signalling in astroglia. *Mol Cell Endocrinol* 2012; 353(1–2): 45–56. [PubMed: 21945602]
54. Verkhratsky A, Untiet V, Rose CR. Ionic signalling in astroglia beyond calcium. *The Journal of physiology* 2020; 598(9): 1655–1670. [PubMed: 30734296]
55. Xu G, Wang W, Kimelberg HK, Zhou M. Electrical coupling of astrocytes in rat hippocampal slices under physiological and simulated ischemic conditions. *Glia* 2010; 58(4): 481–493. [PubMed: 19795502]
56. Verkhratsky A, Nedergaard M. Physiology of Astroglia. *Physiol Rev* 2018; 98(1): 239–389. [PubMed: 29351512]
57. Kiyoshi CM, Zhou M. Astrocyte syncytium: a functional reticular system in the brain. *Neural Regen Res* 2019; 14(4): 595–596. [PubMed: 30632498]
58. Hanani M, Verkhratsky A. Satellite Glial Cells and Astrocytes, a Comparative Review. *Neurochemical research* 2021.
59. Nagai J, Yu X, Papouin T, Cheong E, Freeman MR, Monk KR et al. Behaviorally consequential astrocytic regulation of neural circuits. *Neuron* 2020.
60. Agulhon C, Fiacco TA, McCarthy KD. Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca²⁺ signaling. *Science* 2010; 327(5970): 1250–1254. [PubMed: 20203048]

61. Srinivasan R, Huang BS, Venugopal S, Johnston AD, Chai H, Zeng H et al. Ca²⁺ signaling in astrocytes from *Ip3r2(-/-)* mice in brain slices and during startle responses in vivo. *Nat Neurosci* 2015; 18(5): 708–717. [PubMed: 25894291]
62. Bindocci E, Savtchouk I, Liaudet N, Becker D, Carriero G, Volterra A. Three-dimensional Ca²⁺ imaging advances understanding of astrocyte biology. *Science* 2017; 356(6339).
63. Agarwal A, Wu PH, Hughes EG, Fukaya M, Tischfield MA, Langseth AJ et al. Transient Opening of the Mitochondrial Permeability Transition Pore Induces Microdomain Calcium Transients in Astrocyte Processes. *Neuron* 2017; 93(3): 587–605 e587. [PubMed: 28132831]
64. Kang J, Jiang L, Goldman SA, Nedergaard M. Astrocyte-mediated potentiation of inhibitory synaptic transmission. *Nat Neurosci* 1998; 1(8): 683–692. [PubMed: 10196584]
65. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY et al. Astrocytic purinergic signaling coordinates synaptic networks. *Science* 2005; 310(5745): 113–116. [PubMed: 16210541]
66. Jourdain P, Bergersen LH, Bhaukaurally K, Bezzi P, Santello M, Domercq M et al. Glutamate exocytosis from astrocytes controls synaptic strength. *Nat Neurosci* 2007; 10(3): 331–339. [PubMed: 17310248]
67. Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. *Nature* 2010; 463(7278): 232–236. [PubMed: 20075918]
68. Lee S, Yoon BE, Berglund K, Oh SJ, Park H, Shin HS et al. Channel-mediated tonic GABA release from glia. *Science* 2010; 330(6005): 790–796. [PubMed: 20929730]
69. Durkee CA, Covelo A, Lines J, Kofuji P, Aguilar J, Araque A. Gi/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. *Glia* 2019; 67(6): 1076–1093. [PubMed: 30801845]
70. Parpura V, Basarsky TA, Liu F, Jęftinija K, Jęftinija S, Haydon PG. Glutamate-mediated astrocyte-neuron signalling. *Nature* 1994; 369(6483): 744–747. [PubMed: 7911978]
71. Fiacco TA, Agulhon C, Taves SR, Petravicz J, Casper KB, Dong X et al. Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. *Neuron* 2007; 54(4): 611–626. [PubMed: 17521573]
72. Oberheim NA, Goldman SA, Nedergaard M. Heterogeneity of astrocytic form and function. *Methods Mol Biol* 2012; 814: 23–45. [PubMed: 22144298]
73. Shigetomi E, Bushong EA, Hausteine MD, Tong X, Jackson-Weaver O, Kracun S et al. Imaging calcium microdomains within entire astrocyte territories and endfeet with GCaMPs expressed using adeno-associated viruses. *J Gen Physiol* 2013; 141(5): 633–647. [PubMed: 23589582]
74. Shigetomi E, Kracun S, Sofroniew MV, Khakh BS. A genetically targeted optical sensor to monitor calcium signals in astrocyte processes. *Nat Neurosci* 2010; 13(6): 759–766. [PubMed: 20495558]
75. Hausteine MD, Kracun S, Lu XH, Shih T, Jackson-Weaver O, Tong X et al. Conditions and constraints for astrocyte calcium signaling in the hippocampal mossy fiber pathway. *Neuron* 2014; 82(2): 413–429. [PubMed: 24742463]
76. Duan S, Anderson CM, Keung EC, Chen Y, Swanson RA. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. *J Neurosci* 2003; 23(4): 1320–1328. [PubMed: 12598620]
77. Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. *J Neurosci* 2003; 23(9): 3588–3596. [PubMed: 12736329]
78. Covelo A, Araque A. Neuronal activity determines distinct gliotransmitter release from a single astrocyte. *Elife* 2018; 7.
79. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci* 2002; 22(1): 183–192. [PubMed: 11756501]
80. Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG. Synaptic islands defined by the territory of a single astrocyte. *J Neurosci* 2007; 27(24): 6473–6477. [PubMed: 17567808]
81. Pirttimaki TM, Sims RE, Saunders G, Antonio SA, Codadu NK, Parri HR. Astrocyte-Mediated Neuronal Synchronization Properties Revealed by False Gliotransmitter Release. *J Neurosci* 2017; 37(41): 9859–9870. [PubMed: 28899919]

82. Parpura V, Scemes E, Spray DC. Mechanisms of glutamate release from astrocytes: gap junction “hemichannels”, purinergic receptors and exocytotic release. *Neurochemistry international* 2004; 45(2–3): 259–264. [PubMed: 15145541]
83. Woo DH, Han KS, Shim JW, Yoon BE, Kim E, Bae JY et al. TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation. *Cell* 2012; 151(1): 25–40. [PubMed: 23021213]
84. Park H, Han KS, Seo J, Lee J, Dravid SM, Woo J et al. Channel-mediated astrocytic glutamate modulates hippocampal synaptic plasticity by activating postsynaptic NMDA receptors. *Mol Brain* 2015; 8: 7. [PubMed: 25645137]
85. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci* 2003; 6(7): 743–749. [PubMed: 12778052]
86. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G. Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. *Neuron* 2004; 43(5): 729–743. [PubMed: 15339653]
87. Bardoni R, Ghirri A, Zonta M, Betelli C, Vitale G, Ruggieri V et al. Glutamate-mediated astrocyte-to-neuron signalling in the rat dorsal horn. *The Journal of physiology* 2010; 588(Pt 5): 831–846. [PubMed: 20083514]
88. Santello M, Bezzi P, Volterra A. TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. *Neuron* 2011; 69(5): 988–1001. [PubMed: 21382557]
89. Vance KM, Rogers RC, Hermann GE. PAR1-activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors. *J Neurosci* 2015; 35(2): 776–785. [PubMed: 25589770]
90. Testa CM, Catania MV, Young AB. Anatomical Distribution of Metabotropic Glutamate Receptors in Mammalian Brain. 1994: 99–123.
91. Schools GP, Kimelberg HK. mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats. *Journal of neuroscience research* 1999; 58(4): 533–543. [PubMed: 10533045]
92. Sun W, McConnell E, Pare J-F, Xu Q, Chen M, Peng W et al. Glutamate-Dependent Neuroglial Calcium Signaling Differs Between Young and Adult Brain. *Science* 2013; 339(6116): 197–200. [PubMed: 23307741]
93. Chai H, Diaz-Castro B, Shigetomi E, Monte E, Oceau JC, Yu X et al. Neural Circuit-Specialized Astrocytes: Transcriptomic, Proteomic, Morphological, and Functional Evidence. *Neuron* 2017; 95(3): 531–549 e539. [PubMed: 28712653]
94. Nakahara K, Okada M, Nakanishi S. The metabotropic glutamate receptor mGluR5 induces calcium oscillations in cultured astrocytes via protein kinase C phosphorylation. *J Neurochem* 1997; 69(4): 1467–1475. [PubMed: 9326275]
95. D’Ascenzo M, Fellin T, Terunuma M, Revilla-Sanchez R, Meaney DF, Auberson YP et al. mGluR5 stimulates gliotransmission in the nucleus accumbens. *Proc Natl Acad Sci U S A* 2007; 104(6): 1995–2000. [PubMed: 17259307]
96. Balazs R, Miller S, Chun Y, Cotman CW. Receptor-coupled phospholipase C and adenylyl cyclase function with different calcium pools in astrocytes. *Neuroreport* 1998; 9(7): 1397–1401. [PubMed: 9631436]
97. Sun W, McConnell E, Pare JF, Xu Q, Chen M, Peng W et al. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. *Science* 2013; 339(6116): 197–200. [PubMed: 23307741]
98. Li X, Peng XQ, Jordan CJ, Li J, Bi GH, He Y et al. mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. *Sci Rep* 2018; 8(1): 3686. [PubMed: 29487381]
99. Kenny PJ, Boutrel B, Gasparini F, Koob GF, Markou A. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. *Psychopharmacology (Berl)* 2005; 179(1): 247–254. [PubMed: 15602687]

100. Paterson NE, Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. *Psychopharmacology (Berl)* 2005; 179(1): 255–261. [PubMed: 15619120]
101. Benneyworth MA, Hearing MC, Asp AJ, Madayag A, Ingebretson AE, Schmidt CE et al. Synaptic Depotentiation and mGluR5 Activity in the Nucleus Accumbens Drive Cocaine-Primed Reinstatement of Place Preference. *J Neurosci* 2019; 39(24): 4785–4796. [PubMed: 30948476]
102. Burnstock G. Purinergic nerves. *Pharmacological reviews* 1972; 24(3): 509–581. [PubMed: 4404211]
103. Hepp R, Perraut M, Chasserot-Golaz S, Galli T, Aunis D, Langley K et al. Cultured glial cells express the SNAP-25 analogue SNAP-23. *Glia* 1999; 27(2): 181–187. [PubMed: 10417817]
104. Wilhelm A, Volkandt W, Langer D, Nolte C, Kettenmann H, Zimmermann H. Localization of SNARE proteins and secretory organelle proteins in astrocytes in vitro and in situ. *Neurosci Res* 2004; 48(3): 249–257. [PubMed: 15154671]
105. Koizumi S, Fujishita K, Tsuda M, Shigemoto-Mogami Y, Inoue K. Dynamic inhibition of excitatory synaptic transmission by astrocyte-derived ATP in hippocampal cultures. *Proc Natl Acad Sci U S A* 2003; 100(19): 11023–11028. [PubMed: 12958212]
106. Guthrie PB, Knappenberger J, Segal M, Bennett MV, Charles AC, Kater SB. ATP released from astrocytes mediates glial calcium waves. *J Neurosci* 1999; 19(2): 520–528. [PubMed: 9880572]
107. Lalo U, Pankratov Y, Kirchhoff F, North RA, Verkhratsky A. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. *J Neurosci* 2006; 26(10): 2673–2683. [PubMed: 16525046]
108. Hamilton N, Vayro S, Kirchhoff F, Verkhratsky A, Robbins J, Gorecki DC et al. Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. *Glia* 2008; 56(7): 734–749. [PubMed: 18293404]
109. Queiroz G, Meyer DK, Meyer A, Starke K, von Kugelgen I. A study of the mechanism of the release of ATP from rat cortical astroglial cells evoked by activation of glutamate receptors. *Neuroscience* 1999; 91(3): 1171–1181. [PubMed: 10391492]
110. Abdipranoto A, Liu GJ, Werry EL, Bennett MR. Mechanisms of secretion of ATP from cortical astrocytes triggered by uridine triphosphate. *Neuroreport* 2003; 14(17): 2177–2181. [PubMed: 14625443]
111. Gourine AV, Kasymov V, Marina N, Tang F, Figueiredo MF, Lane S et al. Astrocytes control breathing through pH-dependent release of ATP. *Science* 2010; 329(5991): 571–575. [PubMed: 20647426]
112. Anderson CM, Bergner JP, Swanson RA. ATP-induced ATP release from astrocytes. *J Neurochem* 2004; 88(1): 246–256. [PubMed: 14675168]
113. Koizumi S. Synchronization of Ca²⁺ oscillations: involvement of ATP release in astrocytes. *FEBS J* 2010; 277(2): 286–292. [PubMed: 19895581]
114. Fellin T, Pozzan T, Carmignoto G. Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes. *The Journal of biological chemistry* 2006; 281(7): 4274–4284. [PubMed: 16338906]
115. Zimmermann H, Braun N. Extracellular metabolism of nucleotides in the nervous system. *J Auton Pharmacol* 1996; 16(6): 397–400. [PubMed: 9131425]
116. Deng Q, Terunuma M, Fellin T, Moss SJ, Haydon PG. Astrocytic activation of A1 receptors regulates the surface expression of NMDA receptors through a Src kinase dependent pathway. *Glia* 2011; 59(7): 1084–1093. [PubMed: 21544869]
117. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. *Nat Rev Neurosci* 2015; 16(5): 305–312. [PubMed: 25873042]
118. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2011; 69(12): e145–157. [PubMed: 21550021]
119. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. *Nature* 2013; 493(7433): 537–541. [PubMed: 23235822]

120. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. *Archives of general psychiatry* 2012; 69(8): 776–786. [PubMed: 22474070]
121. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacological reviews* 2011; 63(1): 182–217. [PubMed: 21303898]
122. Karakaya S, Kipp M, Beyer C. Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system. *J Neuroendocrinol* 2007; 19(9): 682–690. [PubMed: 17680883]
123. Zanassi P, Paolillo M, Montecucco A, Avvedimento EV, Schinelli S. Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture. *Journal of neuroscience research* 1999; 58(4): 544–552. [PubMed: 10533046]
124. Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. *Proc Natl Acad Sci U S A* 2001; 98(4): 1964–1969. [PubMed: 11172059]
125. Shao W, Zhang SZ, Tang M, Zhang XH, Zhou Z, Yin YQ et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. *Nature* 2013; 494(7435): 90–94. [PubMed: 23242137]
126. Requardt RP, Hirrlinger PG, Wilhelm F, Winkler U, Besser S, Hirrlinger J. Ca(2)(+) signals of astrocytes are modulated by the NAD(+)/NADH redox state. *J Neurochem* 2012; 120(6): 1014–1025. [PubMed: 22299833]
127. Fischer T, Scheffler P, Lohr C. Dopamine-induced calcium signaling in olfactory bulb astrocytes. *Sci Rep* 2020; 10(1): 631. [PubMed: 31959788]
128. Kebejian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. *Proc Natl Acad Sci U S A* 1972; 69(8): 2145–2149. [PubMed: 4403305]
129. MILLER RJ, HORN AS, IVERSEN LL. The Action of Neuroleptic Drugs on Dopamine-Stimulated Adenosine Cyclic 3',5'-Monophosphate Production in Rat Neostriatum and Limbic Forebrain. *Molecular Pharmacology* 1974; 10(5): 759–766.
130. Galloway A, Adeluyi A, O'Donovan B, Fisher ML, Rao CN, Critchfield P et al. Dopamine Triggers CTCF-Dependent Morphological and Genomic Remodeling of Astrocytes. *J Neurosci* 2018; 38(21): 4846–4858. [PubMed: 29712779]
131. Jennings A, Tyurikova O, Bard L, Zheng K, Semyanov A, Henneberger C et al. Dopamine elevates and lowers astroglial Ca(2+) through distinct pathways depending on local synaptic circuitry. *Glia* 2017; 65(3): 447–459. [PubMed: 27896839]
132. Inazu M, Kubota N, Takeda H, Zhang J, Kiuchi Y, Oguchi K et al. Pharmacological characterization of dopamine transport in cultured rat astrocytes. *Life Sci* 1999; 64(24): 2239–2245. [PubMed: 10374914]
133. Pelton EW 2nd, Kimelberg HK, Shipherd SV, Bourke RS. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. *Life Sci* 1981; 28(14): 1655–1663. [PubMed: 7242252]
134. Asanuma M, Miyazaki I, Murakami S, Diaz-Corrales FJ, Ogawa N. Striatal astrocytes act as a reservoir for L-DOPA. *PloS one* 2014; 9(9): e106362. [PubMed: 25188235]
135. Schomig E, Russ H, Staudt K, Martel F, Gliese M, Grundemann D. The extraneuronal monoamine transporter exists in human central nervous system glia. *Adv Pharmacol* 1998; 42: 356–359. [PubMed: 9327915]
136. Vaarmann A, Gandhi S, Abramov AY. Dopamine induces Ca²⁺ signaling in astrocytes through reactive oxygen species generated by monoamine oxidase. *J Biol Chem* 2010; 285(32): 25018–25023. [PubMed: 20547771]
137. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron* 2016; 89(1): 37–53. [PubMed: 26687838]
138. Petrelli F, Dallerac G, Pucci L, Cali C, Zehnder T, Sultan S et al. Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. *Mol Psychiatry* 2020; 25(4): 732–749. [PubMed: 30127471]

139. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *The Journal of physiology* 1973; 232(2): 331–356. [PubMed: 4727084]
140. Hebb DO. *The Organization of Behavior: A Neuropsychological Theory*. Wiley: NY, 1949.
141. Lichtman JW, Purves D. Activity-mediated neural change. *Nature* 1983; 301(5901): 563. [PubMed: 6828137]
142. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. *Nature* 1986; 319(6056): 774–776. [PubMed: 2869411]
143. Cajal SRy. Estructura de los centros nerviosos de las aves. *Rev Trim Histol Norm Patol* 1888; (1): 1–10.
144. Lushnikova I, Skibo G, Muller D, Nikonenko I. Synaptic potentiation induces increased glial coverage of excitatory synapses in CA1 hippocampus. *Hippocampus* 2009; 19(8): 753–762. [PubMed: 19156853]
145. Perea G, Araque A. Astrocytes potentiate transmitter release at single hippocampal synapses. *Science* 2007; 317(5841): 1083–1086. [PubMed: 17717185]
146. Henneberger C, Bard L, Panatier A, Reynolds JP, Medvedev NI, Minge D et al. Astroglia withdraw from potentiated synapses boosting inter-synaptic cross-talk. *bioRxiv* 2018.
147. Masuoka T, Ikeda R, Konishi S. Persistent activation of histamine H1 receptors in the hippocampal CA1 region enhances NMDA receptor-mediated synaptic excitation and long-term potentiation in astrocyte- and D-serine-dependent manner. *Neuropharmacology* 2019; 151: 64–73. [PubMed: 30943384]
148. Min R, Nevian T. Astrocyte signaling controls spike timing-dependent depression at neocortical synapses. *Nat Neurosci* 2012; 15(5): 746–753. [PubMed: 22446881]
149. Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C et al. Neuroligin 1: a splice site-specific ligand for beta-neurexins. *Cell* 1995; 81(3): 435–443. [PubMed: 7736595]
150. Song JY, Ichtchenko K, Sudhof TC, Brose N. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. *Proc Natl Acad Sci U S A* 1999; 96(3): 1100–1105. [PubMed: 9927700]
151. Ullian EM, Christopherson KS, Barres BA. Role for glia in synaptogenesis. *Glia* 2004; 47(3): 209–216. [PubMed: 15252809]
152. Miller FD, Gauthier AS. Timing is everything: making neurons versus glia in the developing cortex. *Neuron* 2007; 54(3): 357–369. [PubMed: 17481390]
153. Gotz M, Barde YA. Radial glial cells defined and major intermediates between embryonic stem cells and CNS neurons. *Neuron* 2005; 46(3): 369–372. [PubMed: 15882633]
154. Bayer SA, Altman J. *Neocortical development*. 1991.
155. Allen NJ, Eroglu C. *Cell Biology of Astrocyte-Synapse Interactions*. *Neuron* 2017; 96(3): 697–708. [PubMed: 29096081]
156. Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Control of synapse number by glia. *Science* 2001; 291(5504): 657–661. [PubMed: 11158678]
157. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. *Science* 1997; 277(5332): 1684–1687. [PubMed: 9287225]
158. Christopherson KS, Ullian EM, Stokes CC, Mallowney CE, Hell JW, Agah A et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. *Cell* 2005; 120(3): 421–433. [PubMed: 15707899]
159. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor- α . *J Neurosci* 2005; 25(12): 3219–3228. [PubMed: 15788779]
160. Kucukdereli H, Allen NJ, Lee AT, Feng A, Ozlu MI, Conatser LM et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. *Proc Natl Acad Sci U S A* 2011; 108(32): E440–449. [PubMed: 21788491]

161. Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. *Nature* 2012; 486(7403): 410–414. [PubMed: 22722203]
162. Nagler K, Mauch DH, Pfrieger FW. Glia-derived signals induce synapse formation in neurones of the rat central nervous system. *The Journal of physiology* 2001; 533(Pt 3): 665–679. [PubMed: 11410625]
163. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. *Cell* 2009; 139(2): 380–392. [PubMed: 19818485]
164. Adams JC. Thrombospondins: multifunctional regulators of cell interactions. *Annu Rev Cell Dev Biol* 2001; 17: 25–51. [PubMed: 11687483]
165. Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. *Int J Biochem Cell Biol* 2004; 36(6): 1115–1125. [PubMed: 15094126]
166. Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. *Nature* 1995; 375(6530): 400–404. [PubMed: 7760933]
167. Isaac JT, Nicoll RA, Malenka RC. Evidence for silent synapses: implications for the expression of LTP. *Neuron* 1995; 15(2): 427–434. [PubMed: 7646894]
168. Ashby MC, Isaac JT. Maturation of a recurrent excitatory neocortical circuit by experience-dependent unsilencing of newly formed dendritic spines. *Neuron* 2011; 70(3): 510–521. [PubMed: 21555076]
169. Isaac JT, Crair MC, Nicoll RA, Malenka RC. Silent synapses during development of thalamocortical inputs. *Neuron* 1997; 18(2): 269–280. [PubMed: 9052797]
170. Dolphin AC. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. *Nat Rev Neurosci* 2012; 13(8): 542–555. [PubMed: 22805911]
171. Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. *The Journal of physiology* 2016; 594(19): 5369–5390. [PubMed: 27273705]
172. Dolphin AC, Lee A. Presynaptic calcium channels: specialized control of synaptic neurotransmitter release. *Nat Rev Neurosci* 2020; 21(4): 213–229. [PubMed: 32161339]
173. Brown JP, Gee NS. Cloning and deletion mutagenesis of the alpha2 delta calcium channel subunit from porcine cerebral cortex. Expression of a soluble form of the protein that retains [3H]gabapentin binding activity. *The Journal of biological chemistry* 1998; 273(39): 25458–25465. [PubMed: 9738015]
174. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca²⁺ channel alpha2delta ligands: novel modulators of neurotransmission. *Trends Pharmacol Sci* 2007; 28(2): 75–82. [PubMed: 17222465]
175. van Hoof JA, Dougherty JJ, Endeman D, Nichols RA, Wadman WJ. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. *European journal of pharmacology* 2002; 449(3): 221–228. [PubMed: 12167463]
176. Risher WC, Eroglu C. Thrombospondins as key regulators of synaptogenesis in the central nervous system. *Matrix Biol* 2012; 31(3): 170–177. [PubMed: 22285841]
177. Risher WC, Kim N, Koh S, Choi JE, Mitev P, Spence EF et al. Thrombospondin receptor alpha2delta-1 promotes synaptogenesis and spinogenesis via postsynaptic Rac1. *The Journal of cell biology* 2018; 217(10): 3747–3765. [PubMed: 30054448]
178. Dietz DM, Sun H, Lobo MK, Cahill ME, Chadwick B, Gao V et al. Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons. *Nat Neurosci* 2012; 15(6): 891–896. [PubMed: 22522400]
179. Wright WJ, Graziane NM, Neumann PA, Hamilton PJ, Cates HM, Fuerst L et al. Silent synapses dictate cocaine memory destabilization and reconsolidation. *Nat Neurosci* 2020; 23(1): 32–46. [PubMed: 31792465]
180. Xu J, Xiao N, Xia J. Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroigin 1. *Nat Neurosci* 2010; 13(1): 22–24. [PubMed: 19915562]

181. Singh SK, Stogsdill JA, Pulimood NS, Dingsdale H, Kim YH, Pilaz LJ et al. Astrocytes Assemble Thalamocortical Synapses by Bridging NRX1alpha and NL1 via Hevin. *Cell* 2016; 164(1–2): 183–196. [PubMed: 26771491]
182. Takano T, Wallace JT, Baldwin KT, Purkey AM, Uezu A, Courtland JL et al. Chemico-genetic discovery of astrocytic control of inhibition in vivo. *Nature* 2020.
183. Bosworth AP, Allen NJ. The diverse actions of astrocytes during synaptic development. *Curr Opin Neurobiol* 2017; 47: 38–43. [PubMed: 28938161]
184. Jung YJ, Chung WS. Phagocytic Roles of Glial Cells in Healthy and Diseased Brains. *Biomol Ther (Seoul)* 2018; 26(4): 350–357. [PubMed: 29316776]
185. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. *Nature* 2013; 504(7480): 394–400. [PubMed: 24270812]
186. Tung TT, Nagaosa K, Fujita Y, Kita A, Mori H, Okada R et al. Phosphatidylserine recognition and induction of apoptotic cell clearance by Drosophila engulfment receptor Draper. *J Biochem* 2013; 153(5): 483–491. [PubMed: 23420848]
187. Lee JH, Kim JY, Noh S, Lee H, Lee SY, Mun JY et al. Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis. *Nature* 2020.
188. Bialas AR, Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. *Nat Neurosci* 2013; 16(12): 1773–1782. [PubMed: 24162655]
189. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* 2012; 74(4): 691–705. [PubMed: 22632727]
190. Chung WS, Allen NJ, Eroglu C. Astrocytes Control Synapse Formation, Function, and Elimination. *Cold Spring Harb Perspect Biol* 2015; 7(9): a020370. [PubMed: 25663667]
191. Schultz W. Predictive reward signal of dopamine neurons. *J Neurophysiol* 1998; 80(1): 1–27. [PubMed: 9658025]
192. Fiorino DF, Coury A, Fibiger HC, Phillips AG. Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. *Behav Brain Res* 1993; 55(2): 131–141. [PubMed: 7689319]
193. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. *J Neurosci* 2002; 22(15): 6321–6324. [PubMed: 12151508]
194. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. *Proc Natl Acad Sci U S A* 1995; 92(26): 12304–12308. [PubMed: 8618890]
195. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. *Psychological review* 1987; 94(4): 469–492. [PubMed: 3317472]
196. Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. *Brain Res* 1992; 593(2): 314–318. [PubMed: 1450939]
197. Gerrits MA, Petromilli P, Westenberg HG, Di Chiara G, van Ree JM. Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats. *Brain Res* 2002; 924(2): 141–150. [PubMed: 11750899]
198. Parsons LH, Smith AD, Justice JB Jr. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. *Synapse* 1991; 9(1): 60–65. [PubMed: 1796352]
199. Robertson MW, Leslie CA, Bennett JP Jr. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. *Brain Res* 1991; 538(2): 337–339. [PubMed: 2012975]
200. Fontana DJ, Post RM, Pert A. Conditioned increases in mesolimbic dopamine overflow by stimuli associated with cocaine. *Brain Res* 1993; 629(1): 31–39. [PubMed: 8287278]

201. Di Ciano P, Blaha CD, Phillips AG. Conditioned changes in dopamine oxidation currents in the nucleus accumbens of rats by stimuli paired with self-administration or yoked-administration of d-amphetamine. *Eur J Neurosci* 1998; 10(3): 1121–1127. [PubMed: 9753180]
202. Duvauchelle CL, Ikegami A, Asami S, Robens J, Kressin K, Castaneda E. Effects of cocaine context on NAcc dopamine and behavioral activity after repeated intravenous cocaine administration. *Brain Res* 2000; 862(1–2): 49–58. [PubMed: 10799668]
203. Weiss F, Maldonado-Vlaar CS, Parsons LH, Kerr TM, Smith DL, Ben-Shahar O. Control of cocaine-seeking behavior by drug-associated stimuli in rats: effects on recovery of extinguished operant-responding and extracellular dopamine levels in amygdala and nucleus accumbens. *Proc Natl Acad Sci U S A* 2000; 97(8): 4321–4326. [PubMed: 10760299]
204. Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ. Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. *J Neurosci* 2000; 20(19): 7489–7495. [PubMed: 11007908]
205. Neisewander JL, O'Dell LE, Tran-Nguyen LT, Castaneda E, Fuchs RA. Dopamine overflow in the nucleus accumbens during extinction and reinstatement of cocaine self-administration behavior. *Neuropsychopharmacology* 1996; 15(5): 506–514. [PubMed: 8914124]
206. Corkrum M, Covelo A, Lines J, Bellocchio L, Pisansky M, Loke K et al. Dopamine-Evoked Synaptic Regulation in the Nucleus Accumbens Requires Astrocyte Activity. *Neuron* 2020; 105(6): 1036–1047 e1035. [PubMed: 31954621]
207. Pan HT, Menacherry S, Justice JB Jr. Differences in the pharmacokinetics of cocaine in naive and cocaine-experienced rats. *J Neurochem* 1991; 56(4): 1299–1306. [PubMed: 2002342]
208. Pettit HO, Pan HT, Parsons LH, Justice JB Jr. Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. *J Neurochem* 1990; 55(3): 798–804. [PubMed: 2384752]
209. Wang J, Li KL, Shukla A, Beroun A, Ishikawa M, Huang X et al. Cocaine Triggers Astrocyte-Mediated Synaptogenesis. *Biol Psychiatry* 2021; 89(4): 386–397. [PubMed: 33069367]
210. Xin W, Schuebel KE, Jair KW, Cimbri R, De Biase LM, Goldman D et al. Ventral midbrain astrocytes display unique physiological features and sensitivity to dopamine D2 receptor signaling. *Neuropsychopharmacology* 2019; 44(2): 344–355. [PubMed: 30054584]
211. Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. *Proc Natl Acad Sci U S A* 2009; 106(33): 13939–13944. [PubMed: 19666516]
212. Jiang R, Diaz-Castro B, Looger LL, Khakh BS. Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice. *J Neurosci* 2016; 36(12): 3453–3470. [PubMed: 27013675]
213. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Hausteine MD et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. *Nat Neurosci* 2014; 17(5): 694–703. [PubMed: 24686787]
214. Adermark L, Lovinger DM. Electrophysiological properties and gap junction coupling of striatal astrocytes. *Neurochemistry international* 2008; 52(7): 1365–1372. [PubMed: 18396351]
215. Kemp JM, Powell TP. The connexions of the striatum and globus pallidus: synthesis and speculation. *Philosophical transactions of the Royal Society of London Series B, Biological sciences* 1971; 262(845): 441–457. [PubMed: 4399123]
216. Salgado S, Kaplitt MG. The Nucleus Accumbens: A Comprehensive Review. *Stereotact Funct Neurosurg* 2015; 93(2): 75–93. [PubMed: 25720819]
217. Martin R, Bajo-Graneras R, Moratalla R, Perea G, Araque A. Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. *Science* 2015; 349(6249): 730–734. [PubMed: 26273054]
218. Graziane NM, Sun S, Wright WJ, Jang D, Liu Z, Huang YH et al. Opposing mechanisms mediate morphine- and cocaine-induced generation of silent synapses. *Nat Neurosci* 2016; 19(7): 915–925. [PubMed: 27239940]
219. Knackstedt LA, Moussawi K, Lalumiere R, Schwendt M, Klugmann M, Kalivas PW. Extinction training after cocaine self-administration induces glutamatergic plasticity to inhibit cocaine seeking. *J Neurosci* 2010; 30(23): 7984–7992. [PubMed: 20534846]

220. Ghasemzadeh MB, Vasudevan P, Mueller C, Seubert C, Mantsch JR. Neuroadaptations in the cellular and postsynaptic group 1 metabotropic glutamate receptor mGluR5 and Homer proteins following extinction of cocaine self-administration. *Neurosci Lett* 2009; 452(2): 167–171. [PubMed: 19118598]
221. Ghasemzadeh MB, Vasudevan P, Mueller CR, Seubert C, Mantsch JR. Region-specific alterations in glutamate receptor expression and subcellular distribution following extinction of cocaine self-administration. *Brain Res* 2009; 1267: 89–102. [PubMed: 19368820]
222. Ebner SR, Larson EB, Hearing MC, Ingebreton AE, Thomas MJ. Extinction and Reinstatement of Cocaine-seeking in Self-administering Mice is Associated with Bidirectional AMPAR-mediated Plasticity in the Nucleus Accumbens Shell. *Neuroscience* 2018; 384: 340–349. [PubMed: 29885524]
223. Sutton MA, Schmidt EF, Choi KH, Schad CA, Whisler K, Simmons D et al. Extinction-induced upregulation in AMPA receptors reduces cocaine-seeking behaviour. *Nature* 2003; 421(6918): 70–75. [PubMed: 12511956]
224. Scofield MD, Li H, Siemsen BM, Healey KL, Tran PK, Woronoff N et al. Cocaine Self-Administration and Extinction Leads to Reduced Glial Fibrillary Acidic Protein Expression and Morphometric Features of Astrocytes in the Nucleus Accumbens Core. *Biol Psychiatry* 2016; 80(3): 207–215. [PubMed: 26946381]
225. Testen A, Sepulveda-Orengo MT, Gaines CH, Reissner KJ. Region-Specific Reductions in Morphometric Properties and Synaptic Colocalization of Astrocytes Following Cocaine Self-Administration and Extinction. *Front Cell Neurosci* 2018; 12: 246. [PubMed: 30147645]
226. Siemsen BM, Reichel CM, Leong KC, Garcia-Keller C, Gipson CD, Spencer S et al. Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core. *Neuroscience* 2019; 406: 528–541. [PubMed: 30926546]
227. Kruyer A, Scofield MD, Wood D, Reissner KJ, Kalivas PW. Heroin Cue-Evoked Astrocytic Structural Plasticity at Nucleus Accumbens Synapses Inhibits Heroin Seeking. *Biol Psychiatry* 2019; 86(11): 811–819. [PubMed: 31495448]
228. Scofield MD, Boger HA, Smith RJ, Li H, Haydon PG, Kalivas PW. Gq-DREADD Selectively Initiates Glial Glutamate Release and Inhibits Cue-induced Cocaine Seeking. *Biol Psychiatry* 2015; 78(7): 441–451. [PubMed: 25861696]
229. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. *Physiol Rev* 2009; 89(4): 1379–1412. [PubMed: 19789384]
230. Nam MH, Han KS, Lee J, Bae JY, An H, Park S et al. Expression of micro-Opioid Receptor in CA1 Hippocampal Astrocytes. *Exp Neurobiol* 2018; 27(2): 120–128. [PubMed: 29731678]
231. Corkrum M, Rothwell PE, Thomas MJ, Kofuji P, Araque A. Opioid-Mediated Astrocyte-Neuron Signaling in the Nucleus Accumbens. *Cells* 2019; 8(6).
232. Narita M, Miyatake M, Narita M, Shibasaki M, Shindo K, Nakamura A et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. *Neuropsychopharmacology* 2006; 31(11): 2476–2488. [PubMed: 16407899]
233. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. *J Neurosci* 2003; 23(8): 3531–3537. [PubMed: 12716962]
234. Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. *Neuron* 2005; 45(5): 647–650. [PubMed: 15748840]
235. Ma YY, Lee BR, Wang X, Guo C, Liu L, Cui R et al. Bidirectional modulation of incubation of cocaine craving by silent synapse-based remodeling of prefrontal cortex to accumbens projections. *Neuron* 2014; 83(6): 1453–1467. [PubMed: 25199705]
236. Kalivas PW. The glutamate homeostasis hypothesis of addiction. *Nat Rev Neurosci* 2009; 10(8): 561–572. [PubMed: 19571793]
237. Danbolt NC. Glutamate uptake. *Prog Neurobiol* 2001; 65(1): 1–105. [PubMed: 11369436]
238. Bergles DE, Jahr CE. Synaptic activation of glutamate transporters in hippocampal astrocytes. *Neuron* 1997; 19(6): 1297–1308. [PubMed: 9427252]

239. Bergles DE, Jahr CE. Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus. *J Neurosci* 1998; 18(19): 7709–7716. [PubMed: 9742141]
240. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron* 1996; 16(3): 675–686. [PubMed: 8785064]
241. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* 1997; 276(5319): 1699–1702. [PubMed: 9180080]
242. Lehre KP, Danbolt NC. The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. *J Neurosci* 1998; 18(21): 8751–8757. [PubMed: 9786982]
243. Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD, Kalivas PW. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. *Addiction biology* 2015; 20(2): 316–323. [PubMed: 24612076]
244. Roberts-Wolfe DJ, Kalivas PW. Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. *CNS Neurol Disord Drug Targets* 2015; 14(6): 745–756. [PubMed: 26022265]
245. Piet R, Vargova L, Sykova E, Poulain DA, Oliet SH. Physiological contribution of the astrocytic environment of neurons to intersynaptic crosstalk. *Proc Natl Acad Sci U S A* 2004; 101(7): 2151–2155. [PubMed: 14766975]
246. Mitchell SJ, Silver RA. Glutamate spillover suppresses inhibition by activating presynaptic mGluRs. *Nature* 2000; 404(6777): 498–502. [PubMed: 10761918]
247. Vogt KE, Nicoll RA. Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. *Proc Natl Acad Sci U S A* 1999; 96(3): 1118–1122. [PubMed: 9927703]
248. Min MY, Melyan Z, Kullmann DM. Synaptically released glutamate reduces gamma-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. *Proc Natl Acad Sci U S A* 1999; 96(17): 9932–9937. [PubMed: 10449797]
249. LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. *J Neurosci* 2008; 28(12): 3170–3177. [PubMed: 18354020]
250. Boudreau AC, Reimers JM, Milovanovic M, Wolf ME. Cell surface AMPA receptors in the rat nucleus accumbens increase during cocaine withdrawal but internalize after cocaine challenge in association with altered activation of mitogen-activated protein kinases. *J Neurosci* 2007; 27(39): 10621–10635. [PubMed: 17898233]
251. McCutcheon JE, Wang X, Tseng KY, Wolf ME, Marinelli M. Calcium-permeable AMPA receptors are present in nucleus accumbens synapses after prolonged withdrawal from cocaine self-administration but not experimenter-administered cocaine. *J Neurosci* 2011; 31(15): 5737–5743. [PubMed: 21490215]
252. Smith ACW, Scofield MD, Heinsbroek JA, Gipson CD, Neuhofer D, Roberts-Wolfe DJ et al. Accumbens nNOS Interneurons Regulate Cocaine Relapse. *J Neurosci* 2017; 37(4): 742–756. [PubMed: 28123012]
253. Henneberger C, Bard L, Panatier A, Reynolds JP, Kopach O, Medvedev NI et al. LTP induction boosts glutamate spillover by driving withdrawal of astroglia. *bioRxiv* 2020.
254. Chalifoux JR, Carter AG. Glutamate spillover promotes the generation of NMDA spikes. *J Neurosci* 2011; 31(45): 16435–16446. [PubMed: 22072693]
255. Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. *Biol Psychiatry* 2010; 67(1): 81–84. [PubMed: 19717140]
256. Reissner KJ, Brown RM, Spencer S, Tran PK, Thomas CA, Kalivas PW. Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism. *Neuropsychopharmacology* 2014; 39(2): 499–506. [PubMed: 23985782]
257. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. *J Neurosci* 2002; 22(20): 9134–9141. [PubMed: 12388621]

258. Bridges RJ, Natale NR, Patel SA. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. *Br J Pharmacol* 2012; 165(1): 20–34. [PubMed: 21564084]
259. Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. *J Neurosci* 2007; 27(51): 13968–13976. [PubMed: 18094234]
260. Miguens M, Del Olmo N, Higuera-Matas A, Torres I, Garcia-Lecumberri C, Ambrosio E. Glutamate and aspartate levels in the nucleus accumbens during cocaine self-administration and extinction: a time course microdialysis study. *Psychopharmacology (Berl)* 2008; 196(2): 303–313. [PubMed: 17940751]
261. Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. *Biol Psychiatry* 2009; 65(10): 841–845. [PubMed: 19103434]
262. Kupferschmidt DA, Lovinger DM. Inhibition of presynaptic calcium transients in cortical inputs to the dorsolateral striatum by metabotropic GABA(B) and mGlu2/3 receptors. *The Journal of physiology* 2015; 593(10): 2295–2310. [PubMed: 25781000]
263. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. *J Neurosci* 2005; 25(27): 6389–6393. [PubMed: 16000629]
264. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. *Nat Neurosci* 2009; 12(2): 182–189. [PubMed: 19136971]
265. Ducret E, Puaud M, Lacoste J, Belin-Rauscent A, Fouyssac M, Dugast E et al. N-acetylcysteine Facilitates Self-Imposed Abstinence After Escalation of Cocaine Intake. *Biol Psychiatry* 2016; 80(3): 226–234. [PubMed: 26592462]
266. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. *The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions* 2013; 22(5): 443–452.
267. Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM et al. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. *The Journal of clinical psychiatry* 2016; 77(11): e1439–e1446. [PubMed: 27736051]
268. Back SE, Gray K, Santa Ana E, Jones JL, Jarnecke AM, Joseph JE et al. N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial. *Contemp Clin Trials* 2020; 91: 105961. [PubMed: 32087337]
269. Xi ZX, Baker DA, Shen H, Carson DS, Kalivas PW. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. *J Pharmacol Exp Ther* 2002; 300(1): 162–171. [PubMed: 11752112]
270. Hu G, Duffy P, Swanson C, Ghasemzadeh MB, Kalivas PW. The regulation of dopamine transmission by metabotropic glutamate receptors. *J Pharmacol Exp Ther* 1999; 289(1): 412–416. [PubMed: 10087032]
271. Di Castro MA, Chuquet J, Liaudet N, Bhaukaurally K, Santello M, Bouvier D et al. Local Ca²⁺ detection and modulation of synaptic release by astrocytes. *Nat Neurosci* 2011; 14(10): 1276–1284. [PubMed: 21909085]
272. Rusakov DA, Bard L, Stewart MG, Henneberger C. Diversity of astroglial functions alludes to subcellular specialisation. *Trends Neurosci* 2014; 37(4): 228–242. [PubMed: 24631033]
273. Scofield MD, Heinsbroek JA, Gipson CD, Kupchik YM, Spencer S, Smith AC et al. The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. *Pharmacological reviews* 2016; 68(3): 816–871. [PubMed: 27363441]
274. Smaga I, Gawlinska K, Frankowska M, Wydra K, Sadakierska-Chudy A, Suder A et al. Extinction Training after Cocaine Self-Administration Influences the Epigenetic and Genetic

- Machinery Responsible for Glutamatergic Transporter Gene Expression in Male Rat Brain. *Neuroscience* 2020; 451: 99–110. [PubMed: 33065231]
275. Dong Y, Nestler EJ. The neural rejuvenation hypothesis of cocaine addiction. *Trends Pharmacol Sci* 2014; 35(8): 374–383. [PubMed: 24958329]
276. Farhy-Tselnicker I, Allen NJ. Astrocytes, neurons, synapses: a tripartite view on cortical circuit development. *Neural Dev* 2018; 13(1): 7. [PubMed: 29712572]
277. Huang YH, Lin Y, Mu P, Lee BR, Brown TE, Wayman G et al. In vivo cocaine experience generates silent synapses. *Neuron* 2009; 63(1): 40–47. [PubMed: 19607791]
278. Brown TE, Lee BR, Mu P, Ferguson D, Dietz D, Ohnishi YN et al. A silent synapse-based mechanism for cocaine-induced locomotor sensitization. *J Neurosci* 2011; 31(22): 8163–8174. [PubMed: 21632938]
279. Iruela-Arispe ML, Liska DJ, Sage EH, Bornstein P. Differential expression of thrombospondin 1, 2, and 3 during murine development. *Developmental dynamics : an official publication of the American Association of Anatomists* 1993; 197(1): 40–56. [PubMed: 8400410]
280. Spencer S, Brown RM, Quintero GC, Kupchik YM, Thomas CA, Reissner KJ et al. alpha2delta-1 signaling in nucleus accumbens is necessary for cocaine-induced relapse. *J Neurosci* 2014; 34(25): 8605–8611. [PubMed: 24948814]
281. Nagai J, Rajbhandari AK, Gangwani MR, Hachisuka A, Coppola G, Masmanidis SC et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. *Cell* 2019; 177(5): 1280–1292 e1220. [PubMed: 31031006]
282. Lee BR, Ma YY, Huang YH, Wang X, Otaka M, Ishikawa M et al. Maturation of silent synapses in amygdala-accumbens projection contributes to incubation of cocaine craving. *Nat Neurosci* 2013; 16(11): 1644–1651. [PubMed: 24077564]
283. Lee BR, Dong Y. Cocaine-induced metaplasticity in the nucleus accumbens: silent synapse and beyond. *Neuropharmacology* 2011; 61(7): 1060–1069. [PubMed: 21232547]
284. Neumann PA, Wang Y, Yan Y, Wang Y, Ishikawa M, Cui R et al. Cocaine-Induced Synaptic Alterations in Thalamus to Nucleus Accumbens Projection. *Neuropsychopharmacology* 2016; 41(9): 2399–2410. [PubMed: 27074816]
285. Wright WJ, Dong Y. Psychostimulant-Induced Adaptations in Nucleus Accumbens Glutamatergic Transmission. *Cold Spring Harb Perspect Med* 2020.
286. Robinson TE, Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. *Eur J Neurosci* 1999; 11(5): 1598–1604. [PubMed: 10215912]
287. Robinson TE, Gorny G, Mitton E, Kolb B. Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. *Synapse* 2001; 39(3): 257–266. [PubMed: 11169774]




Figure 1. Astrocyte-mediated regulation of transmission at the tripartite synapse.

A Electron microscopic image showing a tripartite synapse in the NAc, in which a glutamatergic axospinous synapse is wrapped by astrocyte processes (scale bar corresponds to 0.5 μm). **B** Diagram illustrating astrocytic mechanisms of glutamate homeostasis at glutamatergic synapses. Specifically, GLT-1 on astrocytes removes synaptically released glutamate, which can be converted to glutamine within astrocytes and transported back into presynaptic terminals. xCT located at perisynaptic astrocytic processes maintains extracellular levels of ambient glutamate. **C** Diagram showing mechanisms of increasing Ca^{2+} in astrocytes, including ER-derived Ca^{2+} release or entry via ionotropic receptors, that play a key role in the signaling pathways employed by astrocytes to regulate glutamate transmission, including ATP-P2Y1, adenosine-A1R, glutamate-mGluR5, and glutamate-mGluR2/3 signaling pathways.




Figure 2. Dysregulation of NAc extracellular glutamate after cocaine experience.

A In drug naïve animals, GLT-1 is a key astrocytic glutamate transporter that maintains low levels of glutamate at synaptic and perisynaptic locations, while xCT is a key astrocytic glutamate antiporter that maintains ambient glutamate levels for tonic activities of mGluRs in the NAc. **B** After withdrawal from cocaine self-administration, astrocytes retract from synapses and both GLT-1- and xCT-mediated regulation of glutamate is compromised, resulting in increased levels of synaptic and perisynaptic glutamate but decreased levels of ambient, extracellular glutamate.




Figure 3. Astrocyte-mediated synaptogenesis after cocaine self-administration.

A Astrocytic TSP2 and neuronal $\alpha 2\delta-1$ constitute a synaptogenic signaling pathway in the developing brain to promote formation of glutamatergic synapses. Both astrocytic TSP2 and neuronal $\alpha 2\delta-1$ are present in the adult NAc in drug naïve animals. **B** Cocaine self-administration induces formation of nascent, AMPAR-silent synapses in the NAc, which is mediated in part by TSP2- $\alpha 2\delta-1$ signaling. These nascent synapses are thought to have relatively immature spine morphology. **C, D** After cocaine withdrawal, some of these newly formed, immature AMPAR-silent synapses are maintained (**C**) and, by recruiting and stabilizing AMPARs, gradually transform into fully mature synapses, resulting in long-term changes of circuit connectivity (**D**).